Mutations in genes related to drug resistance in Mycobacterium leprae isolates from leprosy patients in Korea

ABSTRACTDrug resistance surveillance identified six untreated leprosy patients in the Philippines withMycobacterium lepraefolP1mutations which confer dapsone resistance. Five patients share a village of residence; four who carried the mutation, Thr53Val, were also linked byM. lepraevariable-number tandem repeat (VNTR) strain types. In India,folP1mutations were detected in two relapse patients with a history of dapsone treatment. Mutations were not found in the rifampin target generpoB. These findings indicate that dapsone resistance is being transmitted.

Download Full-text

Recent Advancement in the Diagnosis and Treatment of Leprosy

Current Topics in Medicinal Chemistry ◽

10.2174/1568026618666181025100434 ◽

2018 ◽

Vol 18 (18) ◽

pp. 1550-1558

Author(s):

Muhammad Aamir ◽

Asma Sadaf ◽

Sehroon Khan ◽

Shagufta Perveen ◽

Afsar Khan

Keyword(s):

Vitamin D ◽

Drug Treatment ◽

Mycobacterium Leprae ◽

Neglected Diseases ◽

Specific Drug ◽

Genetic Studies ◽

Vitamin D Receptors ◽

Micro Rnas ◽

Leprosy Patients ◽

Skin Biopsies

Background: Many of the tropical diseases are neglected by the researchers and medicinal companies due to lack of profit and other interests. The Drugs for Neglected Diseases initiative (DNDi) is established to overcome the problems associated with these neglected diseases. According to a report published by the WHO, leprosy (Hansen's disease) is also a neglected infectious disease. Methods: A negligible amount of advancements has been made in last few decades which includes the tools of diagnosis, causes, treatment, and genetic studies of the bacterium (Mycobacterium leprae) that causes leprosy. The diagnosis of leprosy at earlier stages is important for its effective treatment. Recent studies on vitamin D and its receptors make leprosy diagnosis easier at earlier stages. Skin biopsies and qPCR are the other tools to identify the disease at its initial stages. Results: Until now a specific drug for the treatment of leprosy is not available, therefore, Multi-Drug Therapy (MDT) is used, which is hazardous to health. Besides Mycobacterium leprae, recently a new bacterium Mycobacterium lepromatosis was also identified as a cause of leprosy. During the last few years the genetic studies of Mycobacterium leprae, the role of vitamin D and vitamin D receptors (VDR), and the skin biopsies made the treatment and diagnosis of leprosy easier at early stages. The studies of micro RNAs (miRNAs) made it easy to differentiate leprosy from other diseases especially from tuberculosis. Conclusion: Leprosy can be distinguished from sarcoidosis by quantitative study of reticulin fibers present in skin. The treatment used until now for leprosy is multi-drug treatment. The complete genome identification of Mycobacterium leprae makes the research easy to develop target specified drugs for leprosy. Rifampicin, identified as a potent drug, along with other drugs in uniform multi-drug treatment, has a significant effect when given to leprosy patients at initial stages. These are effective treatments but a specific drug for leprosy is still needed to be identified. The current review highlights the use of modern methods for the identification of leprosy at its earlier stages and the effective use of drugs alone as well as in combination.

Download Full-text

Recombinant polypeptide of Mycobacterium leprae as a potential tool for serological detection of leprosy

AMB Express ◽

10.1186/s13568-019-0928-9 ◽

2019 ◽

Vol 9 (1) ◽

Author(s):

Marcelo dos Santos Barbosa ◽

Iara Beatriz Andrade de Sousa ◽

Simone Simionatto ◽

Sibele Borsuk ◽

Silvana Beutinger Marchioro

Keyword(s):

Large Scale ◽

Mycobacterium Leprae ◽

Detection Methods ◽

Recombinant Polypeptide ◽

Cell Reactivity ◽

Tertiary Structures ◽

Leprosy Patients ◽

T Cell Reactivity ◽

Prevention Methods ◽

Scale Detection

AbstractCurrent prevention methods for the transmission of Mycobacterium leprae, the causative agent of leprosy, are inadequate as suggested by the rate of new leprosy cases reported. Simple large-scale detection methods for M. leprae infection are crucial for early detection of leprosy and disease control. The present study investigates the production and seroreactivity of a recombinant polypeptide composed of various M. leprae protein epitopes. The structural and physicochemical parameters of this construction were assessed using in silico tools. Parameters like subcellular localization, presence of signal peptide, primary, secondary, and tertiary structures, and 3D model were ascertained using several bioinformatics tools. The resultant purified recombinant polypeptide, designated rMLP15, is composed of 15 peptides from six selected M. leprae proteins (ML1358, ML2055, ML0885, ML1811, ML1812, and ML1214) that induce T cell reactivity in leprosy patients from different hyperendemic regions. Using rMLP15 as the antigen, sera from 24 positive patients and 14 healthy controls were evaluated for reactivity via ELISA. ELISA-rMLP15 was able to diagnose 79.17% of leprosy patients with a specificity of 92.86%. rMLP15 was also able to detect the multibacillary and paucibacillary patients in the same proportions, a desirable addition in the leprosy diagnosis. These results summarily indicate the utility of the recombinant protein rMLP15 in the diagnosis of leprosy and the future development of a viable screening test.

Download Full-text